SHOW MORE 

Pfizer to supply US with additional 100M doses of vaccine

Full Screen
1 / 2

Chicago Tribune

Surgeon General of the U.S. Jerome Adams, left, elbow-bumps Emergency Room technician Demetrius Mcalister after Mcalister got the Pfizer COVID-19 vaccination at Saint Anthony Hospital in Chicago, on Tuesday, Dec. 22, 2020. (Youngrae Kim/Chicago Tribune via AP, Pool)

WASHINGTON – Pfizer said Wednesday it will supply the U.S. government with an additional 100 million doses of its COVID-19 vaccine under a new agreement between the pharmaceutical giant and the Trump administration.

Pfizer and its German partner BioNTech said that will bring their total current commitment to 200 million doses for the U.S. That should be enough to vaccinate 100 million people with the two-shot regimen. The government also has an option to purchase an additional 400 million doses.

“This new federal purchase can give Americans even more confidence that we will have enough supply to vaccinate every American who wants it by June 2021," said Health and Human Services Secretary Alex Azar in a statement. The cost to taxpayers: $1.95 billion for the additional 100 million doses.

To aid vaccine production, the government said it is using its authority under a Cold War-era law that allows it to direct private manufacturing.

Pfizer's vaccine was the first to be approved for emergency use by the Food and Drug Administration. It has now been joined by another two-shot vaccine from Moderna, developed in close collaboration with the National Institutes of Health. The government began shipping the Pfizer vaccine to states last week, and the one from Moderna this week.

The priority groups for first vaccination include health care workers and nursing home residents. Gradually more Americans will have access to the free vaccines, which have been shown to be highly effective in clinical studies undertaken so far.

Separately, HHS announced it has joined forces with another big pharma company — Merck— to support the large-scale manufacture of a promising treatment for patients suffering from severe COVID-19 illness.

The treatment, still under investigation and not yet approved by the FDA, is known as MK-7110. It has the potential to minimize the damaging effects of an overactive immune response to COVID-19. This immune overdrive unleashes a cascade of effects on the human body, complicating the life-saving efforts of doctors and nurses.